Literature DB >> 2022973

Interstitial chemotherapy for brain tumors: review.

T Tomita1.   

Abstract

An extensive effort to search for curative chemotherapeutic approaches has found no 'breakthrough' in management of patients with malignant brain tumors. Despite the trials with new agents or protocols of multiple agents, systemic chemotherapy has failed to provide reliable clinical response. Interstitial chemotherapy has been practiced for malignant brain tumors with administering chemotherapeutic compounds directly into the tumor which provide increased and prolonged drug concentration in the tumor, reduction of systemic toxicity and bypassing the blood-brain barrier. These theoretical advantages encourage further pursuing interstitial chemotherapy for patients with malignant brain tumors who would otherwise be always fatal. In this review, the literature has been reviewed to identify methods, toxicity, and efficacy of interstitial chemotherapy. Clinical and experimental data indicate limited toxicity and promising efficacy. Various methods to administer the agents were utilized; intraoperative topical application, local injections through catheters or implantable controlled drug delivery system. Selection of ideal chemotherapeutic agents and development of drug delivery system need further investigations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022973     DOI: 10.1007/bf00151247

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  82 in total

1.  Study of effectiveness of bleomycin in rat brain tumor model intravenously and intracerebrally.

Authors:  T S Vats; R A Morantz; G W Wood; S Tilzer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-09       Impact factor: 7.038

2.  Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children.

Authors:  H Takahashi; S Nakazawa; T Shimura
Journal:  J Neurosurg       Date:  1985-01       Impact factor: 5.115

3.  Cell kinetics of human gliomas.

Authors:  T Hoshino; M Barker; C B Wilson; E B Boldrey; D Fewer
Journal:  J Neurosurg       Date:  1972-07       Impact factor: 5.115

4.  Treatment of malignant brain tumors by local methotrexate. A preliminary report.

Authors:  S R Weiss; R Raskind
Journal:  Int Surg       Date:  1969-02

5.  Cerebrospinal fluid perfusion for central nervous system neoplasms.

Authors:  R C Rubin; A K Ommaya; E S Henderson; E A Bering; D P Rall
Journal:  Neurology       Date:  1966-07       Impact factor: 9.910

6.  Permeability characteristics of brain adjacent to tumors in rats.

Authors:  V A Levin; M Freeman-Dove; H D Landahl
Journal:  Arch Neurol       Date:  1975-12

7.  [Local use of cytostatic drugs following removal of glioblastomas].

Authors:  H E Diemath
Journal:  Wien Klin Wochenschr       Date:  1987-10-09       Impact factor: 1.704

8.  [A device for prolonged releasing of anticancer drug--bleomycin (author's transl)].

Authors:  R Katakura; T Mori; K Mineura; J Suzuki
Journal:  No Shinkei Geka       Date:  1980-11

9.  Heuristic modeling of drug delivery to malignant brain tumors.

Authors:  V A Levin; C S Patlak; H D Landahl
Journal:  J Pharmacokinet Biopharm       Date:  1980-06

10.  Studies on the intracerebral injection of bleomycin free and entrapped within liposomes in the rat.

Authors:  G Firth; A S Oliver; R O McKeran
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-06       Impact factor: 10.154

View more
  26 in total

1.  Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies.

Authors:  A Boiardi; A Silvani; A Pozzi; L Fariselli; G Broggi; A Salmaggi
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Intraneoplastic application of metrizamide-containing liposomes: kinetic studies with computed tomography.

Authors:  B Wowra; K Cremer; H Stricker; W J Zeller
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

3.  Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data.

Authors:  A Boiardi; A Salmaggi; A Pozzi; G Broggi; A Silvani
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

4.  Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.

Authors:  Muna Aryal; Natalia Vykhodtseva; Yong-Zhi Zhang; Nathan McDannold
Journal:  J Control Release       Date:  2015-02-24       Impact factor: 9.776

5.  A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme.

Authors:  Roy A Patchell; William F Regine; Paul Ashton; Phillip A Tibbs; Diane Wilson; Diana Shappley; Byron Young
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

6.  Growth-inhibiting effects of intralesional docetaxel and paclitaxel on an experimental model of malignant neuroectodermal tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

Review 7.  Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.

Authors:  Muna Aryal; Costas D Arvanitis; Phillip M Alexander; Nathan McDannold
Journal:  Adv Drug Deliv Rev       Date:  2014-01-22       Impact factor: 15.470

8.  Effects of basic fibroblastic growth factor on the growth of human medulloblastoma xenografts.

Authors:  Pascal Vachon; Christiane Girard; Yves Théorêt
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

9.  Isolation of drug delivery from drug effect: problems of optimizing drug delivery parameters.

Authors:  Mir J Ali; Yot Navalitloha; Michael W Vavra; Eric W-Y Kang; Andrea C Itskovich; Peter Molnar; Robert M Levy; Dennis R Groothuis
Journal:  Neuro Oncol       Date:  2006-03-08       Impact factor: 12.300

10.  Interstitial continuous infusion therapy in a malignant glioma model in rats.

Authors:  Yuichi Tange; Akihide Kondo; Merrill J Egorin; Barbara Mania-Farnell; Georgy M Daneriallis; Hiromichi Nakazaki; Simone T Sredni; Veena Rajaram; Stewart Goldman; Marcelo B Soares; Tadanori Tomita
Journal:  Childs Nerv Syst       Date:  2009-02-11       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.